Two products of Hansoh Pharmaceutical Group (HKG:3692) have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.
Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.
HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.